Ad
related to: niaid
Search results
House COVID origins panel accuses Fauci adviser of obstructing probe, subpoenas him for public...
New York Post· 5 days agoMorens still serves as a senior scientific adviser to the director of the National Institute of...
Risk-Targeted Preventive TB Treatment Works, Particularly With Infection Testing
MedPage Today· 5 days agoLarge real-world analysis homes in on the best strategies in high- and low-burden settings
Study identifies signifiers of severe COVID-19 disease and death
Medical Xpress· 6 days agoCollaborators conducted extensive analyses across many different aspects of the immune responses of more than 1,000 patients across the country...
Zach Edey’s wildly off-target first pitch left Cubs mascot stunned
New York Post· 5 days agoWhile Edey’s errant throw is worthy of earning a spot on the list of worst first pitches ever, there...
SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Call Transcript May 7, 2024 SIGA...
NIH official set to testify before COVID panel on ‘discrepancies’ in pandemic timeline
The Hill via Yahoo News· 4 days agoLawrence Tabak, principal deputy director of the National Institutes of Health (NIH), will testify...
WBEZ and Bookends and Beginnings Present: On Call - An Evening w Dr. Anthony Fauci and Sasha-Ann...
Chicago Sun-Times· 4 days agoWBEZ and Bookends and Beginnings are proud to present Dr. Anthony Fauci on Wednesday, June 26 at...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 days agoUT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine PR Newswire SAN ANTONIO, May 9, 2024 The University of Texas Health Science Center at San Antonio ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...